Table 2.

Dosing in adults and special populations [16]

Patient population	Initial dosing	Maintenance dosing
Adults	45/105 mg daily × 3 days	45/105 mg twice dailya
Hepatic impairment
Child Pugh A−B	45/105 mg daily × 3 days	45/105 mg twice
Child Pugh C	Not recommended, no data studied
Renal impairment
eGFR 30−59	45/105 mg daily	45/105 mg daily
eGFR < 30	Not recommended, no data studied
Poor CYP2D6 metabolizers	45/105 mg daily	45/105 mg daily
Concomitant strong CYP2D6 inhibitor use	45/105 mg daily	45/105 mg daily

eGFR, estimated glomerular filtration rate.

^aDosing should be at least 8 hours apart. Do not exceed 2 tablets in 24 hours.